Tech Company Financing Transactions

Life Biosciences Funding Round

On 4/8/2026, Life Biosciences raised $80 million in Series D funding from private investors.

Transaction Overview

Company Name
Announced On
4/8/2026
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series D
Investors
Proceeds Purpose
The proceeds will support the company's operations into the second half of 2027, including the completion of its recently initiated Phase 1 clinical trial of ER-100 and the continued advancement of its broader Partial Epigenetic Reprogramming (PER) platform across multiple therapeutic indications.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
75 Park Plaza, Level Three
Boston, MA 02116
USA
Email Address
Overview
At Life Biosciences, we are on a mission to reverse and prevent age-related diseases. Our platform, termed partial epigenetic reprogramming, has been shown to rejuvenate cells in preclinical models with profound therapeutic effect. It has the potential to rejuvenate cells and restore function in many age-related diseases. We are the sole company with intellectual property covering the therapeutic use of our partial epigenetic reprogramming technology. We are also the only company to have received FDA approval to advance this technology into human clinical studies. While our initial clinical trial is for optic neuropathies, our science has the potential to bring tremendous benefit to patients suffering from multiple age-related diseases.
Profile
Life Biosciences LinkedIn Company Profile
Social Media
Life Biosciences Company Twitter Account
Company News
Life Biosciences News
Facebook
Life Biosciences on Facebook
YouTube
Life Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jerry McLaughlin
  Jerry McLaughlin LinkedIn Profile  Jerry McLaughlin Twitter Account  Jerry McLaughlin News  Jerry McLaughlin on Facebook
Chief Operating Officer
Michael Ringel
  Michael Ringel LinkedIn Profile  Michael Ringel Twitter Account  Michael Ringel News  Michael Ringel on Facebook
Chief Scientific Officer
Sharon Rosenzweig-Lipson
  Sharon Rosenzweig-Lipson LinkedIn Profile  Sharon Rosenzweig-Lipson Twitter Account  Sharon Rosenzweig-Lipson News  Sharon Rosenzweig-Lipson on Facebook
VP - Administration
Amit Shashank
  Amit Shashank LinkedIn Profile  Amit Shashank Twitter Account  Amit Shashank News  Amit Shashank on Facebook
VP - Manufacturing
Michel Wathier
  Michel Wathier LinkedIn Profile  Michel Wathier Twitter Account  Michel Wathier News  Michel Wathier on Facebook
VP - R & D
Lisa Stanek
  Lisa Stanek LinkedIn Profile  Lisa Stanek Twitter Account  Lisa Stanek News  Lisa Stanek on Facebook


 

 

Browse more venture capital transactions:

Prev: 4/8/2026: Treon venture capital transaction
Next: 4/8/2026: Patlytics venture capital transaction

 

Share this article

 


About Database of VC Transactions

We do our best to record every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary